Skip to content
OpenCapital
Get started
Income StatementBalance SheetCash FlowSegments
Regeneron Pharmaceuticals logo

Regeneron Pharmaceuticals Income Statement

Revenue, expenses, and profitability over time

Regeneron Pharmaceuticals generated $14.9B in trailing twelve-month revenue, up 0.1% year-over-year. Net income was $4.4B with a 29.65% net margin. Diluted EPS is $41.05, which grew 0.0% year-over-year. Based on the Q1 2026 filing.

Total Revenue (TTM)$14.9BOperating Income (TTM)$3.6BNet Income (TTM)$4.4BEps Diluted (TTM)$41.05
Latest FilingQ1 2026
Report Date2026-04-29
Market Cap$64.1B
P/E Ratio14.49
ROE14.55%

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
OCI Unrealized Holding Gain (Loss) on Securities, Net of Tax—$38.1M$22.1M$15.7M$7.1M-$65.8M
Unrealized Gain (Loss) on Securities—$38.1M$22.1M$15.7M$7.1M-$65.8M
OCI Unrealized Holding Gain (Loss) on Securities, Net of Tax—$38.1M$22.1M$15.7M$7.1M-$65.8M
Comprehensive Income (Loss), Net of Tax, Attributable to Parent$849.6M$845.7M$1.4B$1.5B$853.1M$661.6M
Net unrealized gains (losses) on securities still held—$38.1M$22.1M$15.7M$7.1M-$65.8M
Other income, net (Note 6)$0$322M$442.8M$755.8M$176M$201.2M
Revenue From Contract With Customer Excluding Assessed Tax$3.8B$3B$3.7B$3.8B$3.9B$3.6B
Other Comprehensive Income (Loss)$849.6M$845.7M$1.4B$1.5B$853.1M$661.6M

Earnings Per Share

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Basic earnings per share$8.54$7.58$13.24$14.09$8.24$6.99
Diluted earnings per share$8.11$7.27$12.81$13.62$7.87$6.75
Weighted-average shares, basic107.9M106.7M105.1M103.6M104.6M104M
Weighted-average shares, diluted115.1M111.2M108.6M107.2M108.6M107.7M

Other Income & Expense

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Other Charges$0$322M$442.8M$755.8M$176M$201.2M
Interest expense$10.5M$8.7M$3.6M$19.3M$12.2M$12.9M
Other income (expense), net$0$313.3M$439.2M$736.5M$163.8M$188.3M

Income Before Tax

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Income before income taxes$958.1M$905M$1.5B$1.8B$1B$831.2M

Tax

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Income tax expense$40.4M$96.3M$127.1M$303.3M$199.1M$104M

Net Income

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Net income$917.7M$808.7M$1.4B$1.5B$844.6M$727.2M

Operating Expenses

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Acquired in-process research and development$13.8M$12.3M$10M$83.1M$18.7M$101.9M
Research and development$1.4B$1.3B$1.4B$1.5B$1.6B$1.5B
Selling, general and administrative$792.2M$633M$634.2M$657.8M$775M$647.7M
Total operating expenses$2.8B$2.4B$2.6B$2.7B$3B$3B

Operating Income

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Operating income$990.2M$591.7M$1.1B$1B$879.9M$642.9M

Revenue

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Total revenue$3.8B$3B$3.7B$3.8B$3.9B$3.6B